Latest Headlines

  1. PolyPid Completes New Drug Application Submission To FDA For D-PLEX₁₀₀ 6/1/2026

    PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the successful completion of its New Drug Application (“NDA”) submission on a rolling review basis to the U.S. Food and Drug Administration (“FDA”) for D-PLEX100, the Company’s lead product candidate for the prevention of surgical site infections (“SSIs”) in patients undergoing colorectal surgery.

  2. China's Original Innovative Drug Cipepofol Approved For Marketing By The U.S. FDA 6/1/2026

    Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, has officially received marketing approval from the U.S. Food and Drug Administration (FDA), becoming the first China-originated innovative intravenous anesthetic to enter the global market.

  3. Introducing Evosep Proteomics To Standardize And Scale Proteomics For Research And Drug Development 6/1/2026

    Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and pharmaceutical drug development.

  4. Zydus Therapeutics New Drug Application (NDA) For Saroglitazar To Treat Primary Biliary Cholangitis (PBC) Granted Priority Review By The US FDA 5/28/2026

    Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation-led health care company, today announced that the US Food and Drug Administration (US FDA) granted Priority Review to the New Drug Application (NDA) for saroglitazar.

  5. Quotient Sciences Advances AI-Designed Drug Product Into Clinical Development 5/28/2026

    Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial intelligence (AI) - a landmark achievement highlighting the growing potential of AI to guide formulation design and accelerate drug development.

  6. From Hit Identification To Lead Optimization: Building Scientific Continuity In Early Drug Discovery 5/27/2026

    On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry."

  7. Momentum Biotechnologies Launches CHIPP, A Novel High-Throughput Target Deconvolution Technology 5/27/2026

    Momentum Biotechnologies ("Momentum"), a contract research organization that leverages mass spectrometry for drug discovery, announced today the launch of CHIPP (chaotrope-induced protein precipitation and proteome profiling), a novel, sensitive, scalable, and label-free assay for the analysis of drug:target interactions.

  8. Ionetix Announces Approval Of Abbreviated New Drug Application For Gallium Ga-68 Gozetotide (PSMA-11) 5/26/2026

    Ionetix Corporation (“Ionetix”), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space, announced today that the Federal Drug Administration (FDA) has approved its Abbreviated New Drug Application for Gallium Ga-68 gozetotide.

  9. Deepening Focus On Autoimmune Diseases, Empowering AI-Driven Drug Discovery 5/26/2026

    The global population affected by autoimmune diseases continues to grow steadily, driving strong demand for innovative therapeutics and supporting robust expansion of the preclinical CRO market.

  10. Ginkgo Datapoints, Tangible Scientific, And Inductive Bio Launch ADME-One™: A High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier In Drug Discovery 5/26/2026

    Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio.